title: Discontinuation of statin therapy due to muscular side effects: a survey in real life.
abstract: OBJECTIVE
  To assess the burden of statin related muscular symptom in real life.
  
  
  RESULTS
  We conducted a wide survey on 10,409 French subjects. Among these, 2850 (27%) had hypercholesterolemia and 1074 were treated with statins. Muscular symptoms were reported by 104 (10%) statin treated patients and led to discontinuation in 30% of the symptomatic patients. The main prescribed statins were low doses rosuvastatin, atorvastatin and simvastatin. Pains were the most commonly described symptoms (87%) but many patients also reported stiffness (62%), cramps (67%), weakness or a loss of strength during exertion (55%). Pain was localized in 70% but mostly described as affecting several muscular groups. Approximately 38% of patients reported that their symptoms prevented even moderate exertion during everyday activities, while 42% of patients suffered major disruption to their everyday life.
  
  
  CONCLUSIONS
  Muscular symptoms associated with average dosage statin therapy are more frequent than in clinical trials and have a greater impact on patients' life than usually thought.
authors: Unité de Prévention Cardiovasculaire, Service d'Endocrinologie Métabolisme, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France; UPMC Université Paris 06, UMR S 939, F-75013, France. Electronic address: david.rosenbaum@psl.aphp.fr.
authors: D
authors: D
authors: Rosenbaum
authors: J
authors: J
authors: Dallongeville
authors: P
authors: P
authors: Sabouret
authors: E
authors: E
authors: Bruckert
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D004305:Dose-Response Relationship, Drug; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000009:adverse effects*; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D009120:Muscle Cramp / Q000139:chemically induced / Q000503:physiopathology; D018908:Muscle Weakness / Q000139:chemically induced / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D009140:Musculoskeletal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D019821:Simvastatin